
Anlotinib Combo Improves PFS/OS in Extensive-Stage Small Cell Lung Cancer
Combining anlotinib and benmelstobart with chemotherapy significantly prolonged progression-free survival (PFS) and overall survival (OS) among patients with extensive-stage small cell lung cancer (ES-SCLC) across randomized clinical trials, according to …